Startups
2015
LEUKOS BIOTECH SL
Dirección
Carrer de Muntaner 383, 08021 Barcelona, España
Datos financieros
Propiedad de CERCA
Badalona, Spain
2010
Institut de Recerca Contra la Leucèmia Josep Carreras (IJC)
Estado
Estado de la empresaEstado actual de la empresa
Área DeepTech
Descripción
Descripción
Leukos Biotech es una spin-off del Instituto de Investigación contra la Leucemia Josep Carreras centrada en el desarrollo de nuevos tratamientos y herramientas diagnósticas para la leucemia. Leukos ha generado un amplio espacio químico propio de moléculas de primera clase, disponibles por vía oral y que cumplen el perfil de producto diana deseado, con sólidas pruebas de concepto "in vitro", "ex vivo" e "in vivo" en modelos de xenoinjerto y ortotópicos de LMA. El primer candidato, LK02 para LMA y SMD, estará listo para su desarrollo clínico en el 1T2022. Leukos ha validado mAB propios para el diagnóstico y pronóstico de pacientes con LMA en función de la expresión de la diana (que también tiene atributos de biomarcador)
Descripción del producto
Since the establishment of the Josep Carreras Leukaemia Research Institute, the Leukemia Stem Cell research group led by Dr. Risueño develops a research program focused on the development of therapeutic strategies for targeting LSCs. An in silico screening was performed to search for already human-approved drugs that may differentially kill LSCs while sparing healthy hematopoietic stem cells (HSCs).
Leukos Biotech holds a license from Josep Carreras Leukaemia Research Institute covering proprietary use of a family of drugs and antibodies with the potencial for diagnosing, prognosing and treating AML patients developed by Dr. Risueño's team at IJC. After 3 years of comprehensive research on the mechanism of action of known serotonin antagonist drugs on AML cells, and recognizing the strong potential of the target in the oncological setting, the company started a medicinal chemistry program aiming to deliver new compounds with high selectivity, high specificity, oral bioavailability and no BBB crossing. As a result, Leukos Biotech has defined a first-in-class broad chemistry space with blockbuster potential. Its first candidate for AML/MDS started IND-enabling work in August 2020 and will be IND-ready by 4Q 2021.
Leukos Biotech holds a license from Josep Carreras Leukaemia Research Institute covering proprietary use of a family of drugs and antibodies with the potencial for diagnosing, prognosing and treating AML patients developed by Dr. Risueño's team at IJC. After 3 years of comprehensive research on the mechanism of action of known serotonin antagonist drugs on AML cells, and recognizing the strong potential of the target in the oncological setting, the company started a medicinal chemistry program aiming to deliver new compounds with high selectivity, high specificity, oral bioavailability and no BBB crossing. As a result, Leukos Biotech has defined a first-in-class broad chemistry space with blockbuster potential. Its first candidate for AML/MDS started IND-enabling work in August 2020 and will be IND-ready by 4Q 2021.